AI Article Synopsis
- The study evaluated how effective and safe valdoxan (agomelatine) is for treating depression in elderly patients at a psychiatric hospital.
- The research included 20 patients over 60 years old, who took valdoxan for 42 days at doses of 25-50 mg/day.
- The results showed that valdoxan significantly improved symptoms of depression, anxiety, and cognitive function, making it a promising treatment option for mild to moderate depression in elderly inpatients.
Article Abstract
Objective: To assess therapeutic efficacy, tolerability and safety of valdoxan (agomelatine) in the treatment of depression in elderly inpatients of the psychiatric hospital.
Material And Methods: The study included 20 patients, aged 60 years and older, with depression of varying severity. Patients received valdoxan in standard doses 25-50 mg/day during 42 days.
Results: Valdoxan showed a good balanced profile (in terms of indicators of depression, anxiety and anhedonia) of therapeutic response and tolerability in inpatients with mild to moderate depression. The use of valdoxan led to a significant reduction of depressive disorders and anxiety already in the early period of treatment. The severity of anhedonia decreased to the 14th day of treatment. A significant improvement in cognitive functioning of patients was noted to the end of treatment.
Conclusion: Valdoxan can be recommended for treatment of mild and moderate depression in inpatients of psychiatric hospitals.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17116/jnevro201511511155-62 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!